Trial Profile
A case-control, retrospective study analyzing severity of COVID-19 in patients on biologics for allergic disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 25 Jul 2022 New trial record